Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Colorectal Cancer

    Long Beach, CA

    Search
    Colorectal Cancer
    Long Beach, CA
    Show Map
    Map View
    Long Beach, CA
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      96 Colorectal Cancer Trials near Long Beach, CA

      Power is an online platform that helps thousands of Colorectal Cancer patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Nivolumab-relatlimab Combo for Colorectal Cancer

      Los Angeles, California
      This trial is testing a combination of two drugs, relatlimab and nivolumab, for patients with a certain type of colorectal cancer who haven't responded to other treatments. The drugs help the immune system attack the cancer.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Untreated CNS Metastases, Refractory Hypertension, Others
      Must Not Be Taking:Immunotherapy, Regorafenib, TAS-102

      700 Participants Needed

      Sotorasib + Panitumumab for Colorectal Cancer

      Orange, California
      This trial is testing two doses of sotorasib combined with panitumumab in patients with a specific type of colorectal cancer that has not responded to other treatments. Sotorasib targets a genetic mutation in the cancer cells, while panitumumab helps the immune system attack the cancer. The goal is to see if this combination can help patients live longer without their cancer getting worse.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Active Brain Metastases, Hematological Malignancies, Significant GI Disorder, Cardiovascular Disease, Others
      Must Not Be Taking:KRAS G12C Inhibitors

      160 Participants Needed

      Fruquintinib for Colorectal Cancer

      Whittier, California
      High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib for refractory mCRC. Other aims are to learn how safe fruquintinib is and how well it is tolerated by participants. Participants will receive fruquintinib in 4-week treatment cycles until their condition worsens, they do no longer tolerate the treatment or stop the treatment for other reasons. After the last treatment, participants will be checked upon every 3 months until study completion.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Hypertension, Cardiovascular Disease, Others
      Must Not Be Taking:Anticoagulants, TKIs, CYP3A4 Inducers

      78 Participants Needed

      Regorafenib + Pembrolizumab for Colorectal Cancer

      Newport Beach, California
      This trial is testing a combination of regorafenib and pembrolizumab in patients with advanced colorectal cancer. Regorafenib directly attacks cancer cells, and pembrolizumab helps the immune system fight the cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Hypertension, Brain Metastasis, Autoimmune Disease, Others
      Must Not Be Taking:CYP3A4 Inhibitors, CYP3A4 Inducers

      75 Participants Needed

      Telisotuzumab Adizutecan for Colorectal Cancer

      Fullerton, California
      Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given alone. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. This study will be divided into two groups called treatment arms. In arm 1 participants will receive telisotuzumab adizutecan alone. In arm 2 participants will receive SOC alone. Approximately 140 adult participants with CRC will be enrolled in the study in 45 sites worldwide. In arm 1, participants will receive intravenous (IV) doses of telisotuzumab adizutecan alone. In arm 2 Participants will receive SOC alone. The study will run for a duration of approximately 51 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:No Tissue Sample, ILD, Others

      140 Participants Needed

      Isunakinra + Pembrolizumab for Colorectal Cancer

      Newport Beach, California
      This study will enroll patients with colorectal cancer that is locally advanced or metastatic. The tumor must be microsatellite stable (MSS), have a tumor mutational burden that is high (TMB-H) and be kras mutated. Patients must have been treated with available approved treatments already. In this study the investigators are testing a new type of immunotherapy, the potent IL-1 inhibitor isunakinra to be added to already approved immunotherapy (PD-1/PD-L1 inhibitor) in an attempt to get this treatment to work in this treatment resistant type of tumor.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Autoimmune Diseases, HIV, Others
      Must Be Taking:PD-1 Inhibitors

      20 Participants Needed

      ERAS-007 Combination Therapy for Gastrointestinal Cancer

      Orange, California
      This trial is testing a new drug called ERAS-007 combined with other cancer treatments to see if it is safe and effective for patients with advanced gastrointestinal cancers. The study focuses on patients with specific genetic mutations in their cancer cells, which are often hard to treat. ERAS-007 aims to target these mutations to help stop the cancer from growing.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Symptomatic Brain Metastasis, Active Infection, Cardiovascular Disease, Others
      Must Not Be Taking:RAS Inhibitors

      102 Participants Needed

      D-1553 for Solid Tumors

      Orange, California
      This trial is testing a new drug called D-1553 on patients with advanced or metastatic solid tumors that have the KRasG12C mutation. The drug works by blocking a faulty gene in cancer cells to stop tumor growth. Sotorasib and Adagrasib are earlier drugs targeting the KRAS G12C mutation, with Sotorasib being the first to receive FDA approval.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Cardiac Insufficiency, Stroke, Others

      180 Participants Needed

      RO7198457 for Colorectal Cancer

      Orange, California
      This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Illness, Metastatic Disease, Others
      Must Not Be Taking:Immunosuppressants, Investigational Drugs

      327 Participants Needed

      Epacadostat + Chemoradiation for Rectal Cancer

      Orange, California
      The purpose of this research study is to evaluate epacadostat when given with routine radiation therapy and chemotherapy (capecitabine and oxaliplatin) to treat rectal cancer before routine surgery is performed to remove the tumor.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Other Cancer, Metastatic Disease, Autoimmune, Others
      Must Not Be Taking:Warfarin, MAOIs, Others

      49 Participants Needed

      ZEN003694 + Chemotherapy for Colorectal Cancer

      Orange, California
      This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with the usual treatment with capecitabine in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and that it has progressed on previous standard treatment. ZEN003694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that over produce BET protein. Capecitabine is in a class of medications called antimetabolites. It is taken up by cancer cells and breaks down into fluorouracil, a substance that kills cancer cells. Giving ZEN003694 in combination with capecitabine may be safe in treating patients with metastatic or unresectable solid tumors.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:CNS Disease, DPD Deficiency, Others
      Must Be Taking:Capecitabine

      30 Participants Needed

      SHP2 Inhibitor for Solid Cancers

      Fullerton, California
      This trial is testing a new drug called HBI-2376 in patients with advanced solid tumors that have specific genetic changes. The drug aims to block a protein that helps cancer cells grow, potentially stopping or slowing down the cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Concurrent Malignancy, CNS Metastases, Cardiovascular Disease, Autoimmune Diseases, Others
      Must Not Be Taking:Steroids, Immunosuppressants

      42 Participants Needed

      ctDNA-Guided Therapy for Colorectal Cancer

      Orange, California
      This is a phase 1b, prospective, single arm, non-randomized, open-label clinical trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon adenocarcinoma.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Metastases, Recent Surgery, Uncontrolled Illness, Others
      Must Not Be Taking:Investigational Agents

      22 Participants Needed

      Cabozantinib + TAS-102 for Colorectal Cancer

      Orange, California
      This is a phase I clinical trial assessing the safety and recommended phase II dose of cabozantinib in combination with trifluridine/tipiracil (TAS102) in patients with metastatic colorectal carcinoma (mCRC).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Cardiovascular Disorders, Others
      Must Not Be Taking:Anticoagulants, Kinase Inhibitors

      12 Participants Needed

      TORL-3-600 for Advanced Cancer

      Fullerton, California
      This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-3-600 in patients with advanced cancer
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Cardiac Disease, Others
      Must Not Be Taking:Chemotherapy, Biologics

      70 Participants Needed

      RMC-6291 for Solid Cancers

      Orange, California
      This trial tests a new drug, RMC-6291, in adults with advanced cancers that have a specific mutation. The drug aims to block a faulty protein in these cancer cells to stop their growth.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Primary CNS Tumors, Active Brain Metastases, Others
      Must Not Be Taking:KRASG12C (ON) Inhibitors

      222 Participants Needed

      Ponsegromab for Cachexia

      Anaheim, California
      This trial tests Ponsegromab, a new drug, on cancer patients who are losing weight and have high GDF 15 levels. The drug aims to lower GDF 15 to improve appetite and reduce weight loss.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      187 Participants Needed

      Cancer Vaccine for Solid Cancers

      El Segundo, California
      This is a phase 1 study to evaluate the safety, the Recommended Phase 2 Dose (RP2D), and preliminary efficacy of a personalized neoepitope yeast-based vaccine, YE-NEO-001, in subjects who have completed potentially curative therapy for their solid cancer and who would otherwise be entering a period of surveillance for recurrent disease.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disease, Organ Transplant, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids

      16 Participants Needed

      taTME Surgery for Rectal Cancer

      Orange, California
      Radical rectal cancer resection, namely total mesorectal excision (TME), is the cornerstone of the treatment of resectable rectal cancer. In combination with chemotherapy and radiation treatment (CRT), complete TME with negative resection margins is associated with sustained local and systemic control even in locally advanced disease. Over the last 2 decades, laparoscopic and robotic techniques have been increasingly adopted due to reduced surgical trauma and faster patient recovery. Yet, both approaches are associated with equivalent postoperative morbidity and disturbances in sexual, urinary and defecatory function relative to open TME. Furthermore, laparoscopic and robotic TME remain associated with substantial conversion rates and variable rates of TME completeness as a result of the procedural difficulties reaching the low rectum from the abdominal approach. Transanal TME (taTME) with laparoscopic assistance was developed to facilitate completion of TME using a primary transanal endoscopic approach. Transanal TME uses a "bottom-up approach" to overcome the technical difficulties of low pelvic dissection using an abdominal approach. Published results from single-center taTME series and an international registry suggest the short-term procedural and oncologic safety of this approach in resectable rectal cancer. No multicenter phase II study has yet been conducted to validate the procedural safety, functional outcomes or long-term oncologic outcomes of this approach. Study Design: This is a 5-year phase II multicenter single-arm study to evaluate the safety and efficacy of low anterior resection (LAR) with taTME using laparoscopic or robotic assistance in 100 eligible subjects with resectable rectal cancer. Hypothesis: taTME is non-inferior to standard LAR with respect to the quality of the TME achieved.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Inflammatory Bowel Disease, Pregnancy, Others

      100 Participants Needed

      Dostarlimab for Colon Cancer

      Orange, California
      This trial is testing dostarlimab, a drug that helps the immune system fight cancer. It targets patients with a specific type of colon cancer that has certain genetic features and can be surgically removed. Dostarlimab works by helping the immune system recognize and destroy cancer cells.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Metastatic Disease, Lung Disease, Cirrhosis, Others
      Must Not Be Taking:Anticancer, Experimental Therapies

      811 Participants Needed

      Why Other Patients Applied

      "I've had radiation and as far as I know I’m in remission, but my brother passed away with the same condition. I don’t mind helping research for a cure... my husband passed away with pancreatic cancer. I've had a stepdaughter that passed away with ovarian cancer at 20. I just think it’s time to knock cancer out! I'd really like to help find better treatments by participating in a trial."

      EQ
      Lung Cancer PatientAge: 70

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "I had two chemotherapy regímens without success, three surgeries during which the tumor could not be resected. These clinical trials are a light of hope for me and my family (I have a five year old child) and I have read about cases of success in other types of cancer with this treatment. I think that I am a perfect candidate for this tríal. Thank you."

      UM
      Pancreatic Cancer PatientAge: 48

      "My mom has cholangiocarcinoma with bone mts (FGFR2 mutation). She really needs this trial to survive. She’s active and her analysis is ok, but we have very limited other options. Hope to work with a high-quality clinic to prolong her quality and duration of life."

      OF
      Cholangiocarcinoma PatientAge: 54

      "I've tried chemotherapy and radiation but the cancer recurred. My oncologist suggested that I might want to try a clinical trial given my situation. Just starting to research, hoping to learn more."

      FR
      Lung Cancer PatientAge: 71
      Match to a Colorectal Cancer Trial

      Decoy20 for Solid Tumors

      Newport Beach, California
      INDP-D101 is a Phase 1/2, open-label, multi-center, dose escalation and expansion study evaluating the safety, tolerability and clinical activity of Decoy20 as monotherapy and in combination with tislelizumab in patients with locally advanced or metastatic solid tumors.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Active Infection, CNS Metastases, Others
      Must Not Be Taking:Corticosteroids, Chemotherapy, Immunotherapy, Others

      120 Participants Needed

      ELI-002 for Colorectal Cancer

      Orange, California
      This trial is testing a new treatment called ELI-002 7P for patients with specific types of cancer. The treatment helps the immune system recognize and attack these cancer cells. ELI-002 7P targets mutations that are common in various cancers and have been studied for their role in tumor growth and resistance to treatments.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Others
      Must Not Be Taking:Immunosuppressive Drugs

      158 Participants Needed

      RMC-6236 for Cancer

      Orange, California
      This trial is testing a new drug called RMC-6236, which is taken by mouth and targets a protein called RAS. It is aimed at adults with advanced cancers that have specific mutations in the RAS protein. The drug works by blocking this protein, which helps stop the cancer cells from growing.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Tumors, Brain Metastases, GI Impairment, Others

      754 Participants Needed

      LY3537982 for Cancer

      Newport Beach, California
      This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Infection, Cardiac Condition, Autoimmune, Others
      Must Not Be Taking:Steroids, KRAS Inhibitors

      540 Participants Needed

      MCLA-129 for Non-Small Cell Lung Cancer

      Orange, California
      This trial tests a new drug, MCLA-129, on its own in patients with advanced cancers who did not respond to previous treatments. The study will adjust doses to find the safest and most effective amount.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Cardiovascular Disease, Others
      Must Not Be Taking:Steroids, Anticancer, Immunotherapy, Others

      576 Participants Needed

      Engineered T-Cell Therapy for Cancer

      Newport Beach, California
      This trial tests NT-175, a personalized treatment made from a patient's own immune cells, in patients with advanced cancers that have a specific genetic mutation. The treatment works by enhancing the immune system to attack cancer cells.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:CNS Malignancy, Cardiac Disease, Others
      Must Not Be Taking:Immunosuppressants, Aminoglycosides

      162 Participants Needed

      Ceralasertib + Trastuzumab Deruxtecan for Solid Tumors

      Orange, California
      The dose escalation phase of this trial identifies the safety, side effects and best dose of ceralasertib (AZD6738) when given in combination with trastuzumab deruxtecan (DS-8201a) in treating patients with solid tumors that have a change (mutation) in the HER2 gene or protein and have spread to other places in the body (advanced). The dose expansion phase (phase Ib) of this trial compares how colorectal and gastroesophageal cancers with HER2 mutation respond to treatment with a combination of ceralasertib and trastuzumab deruxtecan versus trastuzumab deruxtecan alone. Ceralasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers deruxtecan to kill them. Ceralasertib and trastuzumab deruxtecan may be safe, tolerable and effective in treating patients with advanced solid tumors expressing the HER2 protein or gene.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Interstitial Lung Disease, Myocardial Infarction, Uncontrolled Infection, Others
      Must Not Be Taking:CYP3A Inhibitors, Chloroquine

      51 Participants Needed

      NT-112 for Solid Tumors

      Newport Beach, California
      This trial tests NT-112, a personalized immune cell treatment, in patients with advanced cancers that have a specific genetic mutation. The treatment boosts the patient's immune cells to target and kill cancer cells. This highly personalized cancer therapy involves giving the patient immune cells that directly attack cancer.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:CNS Malignancy, Cardiac Disease, Others
      Must Not Be Taking:Immunosuppressants, Systemic Steroids

      24 Participants Needed

      IAM1363 for Breast Cancer

      Los Angeles, California
      This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Cardiac Disease, HIV, Liver Disease, Diabetes, Others

      243 Participants Needed

      TBio-4101 + Pembrolizumab for Advanced Solid Cancers

      Irvine, California
      A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      60 Participants Needed

      1234

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Colorectal Cancer clinical trials in Long Beach, CA pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Colorectal Cancer clinical trials in Long Beach, CA work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Colorectal Cancer trials in Long Beach, CA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Long Beach, CA for Colorectal Cancer is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Long Beach, CA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Colorectal Cancer medical study in Long Beach, CA?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Colorectal Cancer clinical trials in Long Beach, CA?

      Most recently, we added Pumitamig + Chemotherapy for Colorectal Cancer, LY4337713 for Cancer and Telisotuzumab Adizutecan for Colorectal Cancer to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in California

      Anxiety Clinical Trials in California

      Schizophrenia Clinical Trials in California

      ADHD Clinical Trials in California

      Bipolar Disorder Clinical Trials in California

      Multiple Sclerosis Clinical Trials in California

      Autism Clinical Trials in California

      Treatment Resistant Depression Clinical Trials in California

      Borderline Personality Disorder Clinical Trials in California

      Social Anxiety Disorder Clinical Trials in California

      Parkinson's Disease Clinical Trials in California

      Alzheimer's Disease Clinical Trials in California

      By Location

      Clinical Trials near Los Angeles, CA

      Clinical Trials near San Francisco, CA

      Clinical Trials near San Diego, CA

      Clinical Trials near Sacramento, CA

      Clinical Trials near La Jolla, CA

      Clinical Trials near Orange, CA

      Clinical Trials near Stanford, CA

      Clinical Trials near Palo Alto, CA

      Clinical Trials near Long Beach, CA

      Clinical Trials near Duarte, CA

      Clinical Trials near Oakland, CA

      Clinical Trials near Torrance, CA

      Other People Viewed

      By Subject

      23 Colorectal Cancer Trials near Las Vegas, NV

      145 Prostate Cancer Trials near Ventura, CA

      131 Colorectal Cancer Trials near Los Angeles, CA

      181 Clinical Trials near Glenwood Springs, CO

      107 Clinical Trials near Chilton, WI

      113 Lung Cancer Trials near Long Beach, CA

      110 Colorectal Cancer Trials near Austin, TX

      170 Clinical Paid Trials near Long Beach, CA

      45 Lymphedema Trials near Long Beach, CA

      Top Breast Cancer Clinical Trials near Long Beach, CA

      Top Prostate Cancer Clinical Trials near Long Beach, CA

      Top Colorectal Cancer Clinical Trials near Phoenix, AZ

      By Trial

      Encorafenib + Cetuximab for Colorectal Cancer

      Fruquintinib + FOLFIRI for Colorectal Cancer

      Immunotherapy + Chemotherapy for Gastrointestinal Cancer

      Immunotherapy + Radiation for Colorectal and Lung Cancer

      Trastuzumab + Pertuzumab vs. Cetuximab + Irinotecan for Colorectal Cancer

      LY3214996 + Cetuximab / Abemaciclib for Colorectal Cancer

      Drug Combination for Advanced Colorectal Cancer

      Vitamin D3 + Chemotherapy + Bevacizumab for Colorectal Cancer

      Nivolumab-relatlimab Combo for Colorectal Cancer

      Adagrasib + Cetuximab + Cemiplimab for Colorectal Cancer

      Palbociclib + Cetuximab for Colon Cancer

      Radiation and Cisplatin ± Cetuximab for Oropharyngeal Cancer

      Related Searches

      Top Colorectal-cancer Clinical Trials near Glendale, AZ

      Top Colorectal-cancer Clinical Trials near San Diego, CA

      Top Colorectal-cancer Clinical Trials near Phoenix, AZ

      Top Overweight Clinical Trials

      Top Skin-cancer Clinical Trials

      Top Congestive-heart-failure Clinical Trials

      Top Menopause Clinical Trials

      PF-07284892 Combination Therapy for Solid Tumors

      Sonic Augmentation Technology for Emotional Health

      Novobiocin for Cancer

      Toripalimab + Chemotherapy for Nasopharyngeal Cancer

      Glofitamab Combinations for Richter's Transformation